Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction:
- Share Price: 1,382.27 pence per share.
- Transaction Date: January 7, 2013.
- Shares Acquired: 26,951 ordinary shares.
Material Changes
The filing reports an increase in the personal holding of ordinary shares by a connected person, Mrs. K Thomson, following the re-investment of a dividend paid to shareholders on January 3, 2013. No material changes to the company's overall financial position or operations are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a connected person's share purchase in compliance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total dividend reinvestment program details for the January 3, 2013 payment date.
- Confirm the total shareholding of Mrs. K Thomson post-transaction to assess concentration of interest.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive metrics.